 |
 |
I don't really know. That wee French study just caught my eye because it was something so different from anything else I had read on isomers. If it means anything at all then we have to see the difference in clinical results and I think the experts say the clinical trials do not show enough of a difference to justify the expense of escitalopram over citalopram. Lundbeck say different, of course. My own impression is that escitalopram is a cleaner drug and better for anxiety but that would be almost meaningless, were it not for the fact that we all know there is a big gap between our everday patients in the surgery and those who get on to RCTs. And of course I am a dark agent of big pharma anyway since I have earned maybe 2K in the last few years speaking at events organised by Lundbeck. But I have to agree with Adrian about the board drug advisers I have encountered--nice people but second rate. Declan <<Our HB pharmacology adviser just shook his head wearily and declared that "the jury is still out". Is it?>>